SS
GLUE icon

SBI Securities’s Monte Rosa Therapeutics GLUE Stock Holding History

SBI Securities’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.4K Sell
223
-9
-4% -$170 ﹤0.01% 2138
2026
Q1 		$3.82K Sell
232
-6
-3% -$115 ﹤0.01% 2139
2025
Q4 		$3.73K Sell
238
-80
-25% -$1.08K ﹤0.01% 2145
2025
Q3 		$2.36K Buy
318
+48
+18% +$254 ﹤0.01% 2361
2025
Q2 		$1.22K Sell
270
-412
-60% -$1.84K ﹤0.01% 2591
2025
Q1 		$3.16K Buy
682
+30
+5% +$184 ﹤0.01% 2085
2024
Q4 		$4.53K Buy
+652
New +$4.89K ﹤0.01% 1961

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SBI Securities's GLUE Position: Q2 2026 in Review

SBI Securities reduced its Monte Rosa Therapeutics (GLUE) stake by 3.9% in Q2 2026, selling an estimated $170 and leaving 223 shares worth $5.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2138.

SBI Securities first reported a position in GLUE in Q4 2024 and has held it in 7 quarters since. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • SBI Securities held 223 shares of Monte Rosa Therapeutics worth $5.4K as of Q2 2026.
  • SBI Securities sold 9 Monte Rosa Therapeutics shares in Q2 2026, an estimated $170.
  • Monte Rosa Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #2138 holding.
  • SBI Securities first reported a position in Monte Rosa Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.